SLC5A2 and cancer: Considering previous studies, pharmacological agents targeting metabolic pathways, including biguanides (metformin), thiazolidinediones, sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors, and HMG‐CoA reductase inhibitors (statins) are being investigated for potential repurposing in cancer prevention and adjuvant therapy.